NDA Submission

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Staff Reporter October 24, 2023 0

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)...

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024

SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Interesting Stories For You

Sculpt Clinics Introduces New Laser Hair Removal Technology

HEAL Foundation Announces Healthcare CSR Summit & Awards in New Delhi

Apsara Ice Creams to launch Muskaan initiative on its 53rd anniversary

Milann Fertility Center Celebrates World Breastfeeding Week with ‘Milann’s Embrace’ Initiative

DCN Dx to Showcase New Technologies at NextGen Dx 2024